Lignocaine and indocyanine green kinetics in patients following myocardial infarction.
- 1 October 1980
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 10 (4) , 353-361
- https://doi.org/10.1111/j.1365-2125.1980.tb01771.x
Abstract
1. Blood clearances of lignocaine and indocyanine green together with indocyanine green half-lives were measured in 17 post-myocardial infarct patients (one patient was studied twice) between 8 h and 36 h after starting intravenous lignocaine infusions for the treatment of cardiac arrhythmias. 2. Mean +/- s.d. values of lignocaine clearance (ml min-1 kg-1) were higher in patients without heart failure (11.8 +/- 2.6, n = 9) than in those with heart failure (7.2 +/- 1.9, n = 9) (P < 0002). 3. Clearances of lignocaine and indocyanine green were not correlated but lignocaine clearance was directly related to the reciprocal of indocyanine green half-life (rs = 0.67, P < 0.01). 4. In eight patients who received both lignocaine and indocyanine green and in a further five patients received only lignocaine and whose lignocaine infusions lasted 24h or more, a 25% rise in lignocaine concentrations was observed between 8-12h and 24-28h. 5. The mean +/- s.d. post-infusion terminal half-life of lignocaine in four patients whose lignocaine infusions lasted 30h or longer was 7.2 +/- 2.1 h. 6. Heart failure was associated with greater changes in lignocaine kinetics than in indocyanine green kinetics. 72% of the variance between observed and predicted lignocaine clearances could be accounted for by multiple linear regression analysis incorporating indocyanine green half-life and the presence or absence of heart failure. Indocyanine green half-life contributed only 17% of the variance indicating that by itself it is of limited value in predicting lignocaine requirements. 7. Lignocaine kinetics during and after prolonged intravenous infusion were not predicted by data obtained after intravenous bolus injection. 8. A lowering of lignocaine dosage may be clinically desirable in the presence of heart failure and if an infusion lasts longer than 24 h.Keywords
This publication has 21 references indexed in Scilit:
- Cytochrome P-450 and hepatic drug biotransformation during progressive cardiac disease in cardiomyopathic hamstersCanadian Journal of Physiology and Pharmacology, 1979
- Reduced drug elimination in congestive heart failureThe American Journal of Medicine, 1978
- Lidocaine Kinetics Predicted by Indocyanine Green ClearanceNew England Journal of Medicine, 1978
- Clinical Pharmacokinetics of LignocaineClinical Pharmacokinetics, 1978
- Hepatic clearance of local anesthetics in manJournal of Pharmacokinetics and Biopharmaceutics, 1977
- Impaired Lignocaine metabolism in patients with myocardial infarction and cardiac failure.BMJ, 1976
- GLC analysis of lidocaine in blood using an alkaline flame‐ionization detectorJournal of Pharmaceutical Sciences, 1976
- Logical approach to lignocaine therapy.BMJ, 1976
- Evaluation of lidocaine resistance in man using intermittent large-dose infusion techniquesThe American Journal of Cardiology, 1974
- Interrelationships of Hepatic Blood Flow, Cardiac Output, and Blood Levels of Lidocaine in ManCirculation, 1971